Dzoanet, as you described it, PTX-200 might be considered as an "ingredient" of Cell-Pryme-M and CellPryme-A.
CellPryme-M is a manufacturing step in the preparation of cell therapies in which PTX-200, as an example of an AKT inhibitor and PH domain inhibitor, may be used in a medium in which cells are cultured.
CellPryme-A is an adjuvant therapy for cellular therapy in which PTX-200 may be used, but likely in combination with a checkpoint inhibitor.
These are new inventions and therefore require new names. I don’t have a problem with that.
If the supposition of PTX playing a crucial role in both CellPryme-M and CellPryme-A is correct, as a shareholder, I’m happy to see the company very cleverly working to derive maximum value from an existing asset.
- Forums
- ASX - By Stock
- PTX
- Ann: AGM Presentation
Ann: AGM Presentation, page-33
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.4¢ |
Change
0.003(7.32%) |
Mkt cap ! $35.43M |
Open | High | Low | Value | Volume |
4.1¢ | 4.4¢ | 4.0¢ | $20.95K | 507.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 216927 | 4.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.4¢ | 238807 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 216927 | 0.040 |
4 | 374358 | 0.039 |
3 | 750222 | 0.038 |
9 | 742682 | 0.037 |
7 | 598944 | 0.036 |
Price($) | Vol. | No. |
---|---|---|
0.044 | 238807 | 2 |
0.045 | 423919 | 4 |
0.046 | 298002 | 2 |
0.047 | 488389 | 2 |
0.048 | 200000 | 1 |
Last trade - 16.10pm 09/07/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |